Source link : https://newshealth.biz/health-news/myasthenia-gravis-complement-inhibitor-meets-primary-endpoint-in-phase-iii-trial/
(MedPage Today) — SAN FRANCISCO — Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from the phase III PREVAIL… Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118297 Author : Publish date : 2025-11-03 22:43:00 Copyright for syndicated content belongs to the linked Source.
The post Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial first appeared on News Health.
—-
Author : News Health
Publish date : 2025-11-03 22:43:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8